A Nigerian vaccinologist, Simon Agwale, has presented a report of an
experimental vaccine for the dreaded Ebola virus disease to a scientific
conference in France.
In a statement, Yuri Nakamoto, on behalf
of the scientific committee of the conference organised by the Pasteur
Institute, Paris, said the report was one of the items discussed at the
two-day conference.
The International Conference Targeting Ebola
had more than 300 delegates from 42 countries in attendance, Mr.
Nakamoto said in the statement.
He said that the agenda of the
conference included 140 oral, short and posters communications, latest
developments in the Ebola outbreak in Africa, and latest clinical
developments.
Others were latest innovations, vaccines and drugs
to combat Ebola, and prevention of Ebola contamination and transmission,
to be published by the committee.
“Agwale, alongside Epie E. and
Pushko P. of Innovative Biotech Ltd, Keffi, Nasarawa State, and
Innovative Biotech USA Inc, made a presentation on ‘Construction and
Evaluation of a Highly Immunogenic EBOLA Influenza VLP Vaccine
Candidate’.
“They prepared and evaluated EBOV VLPs that included
GP of EBOV Zaire strain in which VLPs were expressed using recombinant
baculovirus in Sf9 cells.
He quoted the researchers as saying
that they had developed and evaluated an EBOV candidate vaccine that was
highly immunogenic in mice.
“Given the immediate need for an
Ebola vaccine and the efficiency, safety and adaptability of our VLP
platform technology, we are confident in producing a high yield, high
quality product using the most cost effective methodologies available,
they said.
The researchers said that the vaccine approach could
be used for mass vaccination in Africa to prevent EBOV infections and
future epidemics of the deadly disease.
They announced that they
were also using their platform technology to develop vaccines against
HIV, malaria and other diseases that plaque Africa.
http://www.premiumtimesng.com/news/more-news/184261-nigerian-scientist-presents-ebola-vaccine-report-in-france.html
No comments:
Post a Comment